NVS Novartis AG Common Stock

-0.23  -0%
Previous Close 81.29
Open 81.12
Price To book 2.85
Market Cap 191.76B
Shares 2,365,595,000
Volume 2,479,805
Short Ratio 1.36
Av. Daily Volume 2,637,670

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 updated data due at ASCO June 4, 2017.
Ribociclib + Letrozole - MONALEESA-2
Breast cancer
Regulatory filing due 2H 2017.
GP2013 - Biosimilar rituximab
Non-Hodgkin’s Lymphoma
Phase 3 trial to commence in 2017.
Ruxolitinib - REACH 3
Steroid-refractory chronic GVHD (Graft versus host disease)
Phase 3 enrollment commenced March 2017.
Ruxolitinib - REACH 2
Steroid-refractory acute GVHD (Graft versus host disease)
Phase 2 pivotal trial dosing initiation announced December 30, 2016.
Ruxolitinib - REACH 1
Steroid-refractory acute GVHD (Graft versus host disease)
Priority review granted February 22, 2017. PDUFA estimate for sNDA June 22, 2017 using 6-month timeline following receipt of sNDA.
First-line use in patients with ALK+ metastatic NSCLC
Phase 2 complete. Regulatory filing due 2018.
Sickle Cell Disease Pain Crises (SCPC)
Phase 3 data due 2Q 2017.
ACZ885 (canakinumab) - CANTOS
CV risk reduction
Phase 3 data released March 22, 2017 - primary endpoints not met.
Acute heart failure
Phase 3 data due mid-2017.
RTH258 (brolucizumab)
Neovascular AMD
Phase 3 data due 2018.
Phase 3 data due 2019.
QAW039 (fevipiprant)
Phase 3 data 2H 2017.
Breast cancer - (pre-menopausal)
Phase 3 data due 2019.
OMB157 (ofatumumab)
Relapsing multiple sclerosis
Phase 3 data due 2H 2017.
Breast cancer - (post-menopausal)
Phase 3 trial completion due 2018.
Entresto - PIONEER
In-hospital initiation vs. enalapril following ADHF (acute decompensated heart failure)
Phase 3 trial completion due 2018.
Pre- vs. postdischarge initiation following ADHF (acute decompensated heart failure)
Phase 3 interim analysis due 2018. Filing 2019.
Entresto - PARAGON
HF-pEF (heart failure with preserved ejection fraction)
Phase 3 trial completion due 2019. Filing 2020.
Entresto - PARADISE
AMI (acute myocardial infarction)
Interim Phase 2 analysis originally scheduled for 1Q 2017, now due at the International Conference on Malignant Lymphoma, June 14, 2017.
Cancer - Diffuse Large B-Cell Lymphoma (DLBCL)
BLA acceptance under priority review announced March 29, 2017. No PDUFA date given. Assume 6-month review - August 29, 2017.
Relapsed/Refractory B-Cell Acute lymphoblastic leukemia
Phase 3 positive data released. Regulatory discussions ongoing.
Secondary progressive multiple sclerosis
Phase 3 data due 2018.
AIN457 (Cosentyx)
Non-radiographic axial SpA
Phase 2/3 ongoing.
CNP 520
Alzheimer’s Disease
Phase 3 trial met primary endpoint September 2016. BLA filing announced May 18, 2017.
Priority review granted November 14, 2016. Approval announced April 28, 2017.
Rydapt (Midostaurin - PKC412)
Acute myeloid leukemia (AML)
Priority review granted November 1, 2016. Approval announced March 13, 2017.
HR+/HER2- advanced breast cancer
BLA filing 2017.
Rheumatoid Arthritis

Latest News

  1. Wide-Moat Roche Is Undervalued
  2. The Current State Of The Breast Cancer Treatment Space
  3. Novartis' (NVS) Lung Cancer Drug Gets Positive CHMP Opinion
  4. Will Novartis' MS Drug Stomp Celgene's Before It Even Hits The Market?
  5. Amgen (AMGN) Submits BLA to FDA for Migraine Drug Erenumab
  6. CHMP backs Novartis's Zykadia for first-line use in lung cancer
  7. Conference Spotlights Drug Giant Donnybrooks In Cancer Treatments
  8. Novartis to cut around 500 jobs in Switzerland, add 350
  9. Today's Research Reports on Stocks to Watch: GlaxoSmithKline and Novartis
  10. GlaxoSmithKline Could Buy Out Partner Novartis
  11. Can Teva Hold Its Own In Bringing Migraine Drugs To Market?
  12. Pharma Stock Roundup: Merck, Pfizer Report Q1 Earnings, J&J Talc Powder Lawsuit
  13. DURECT and Sandoz have Signed a $293 Million Development and Commercialization Agreement for POSIMIR® (SABER®-Bupivacaine) Covering the United States
  14. Barron's Picks And Pans: Amazon, Novartis, Tesla And More
  15. [$$] Novartis Has the Right Prescription for Profits
  16. Conatus (CNAT) Q1 Loss Narrows Y/Y, Revenues Beat Estimates
  17. Blog Coverage: Novartis Exercises Option for Global Development and Commercialization of Conatus Pharmaceuticals' Drug Emricasan
  18. Ophthotech (OPHT) Q1 Loss Narrower than Expected, Sales Miss
  19. Novartis, Roche back French gene therapy start-up Vivet
  20. Novartis exercises option with Conatus for NASH product